CAS: 5409-37-0; N6,N6,2-Trimethylacridine-3,6-Diamine Hydrochloride

专利信息

专利号:US-8563261-B2
优先权日:2009-09-28
标 题:Method of diagnosing and treating interstitial cystitis
发明人：CHACKO SAMUEL K
权利人:CHACKO SAMUEL K; UNIV PENNSYLVANIA
摘要:A method for diagnosing, or differentially diagnosing, interstitial cystitis (IC) involves detecting or measuring increased expression of a biomarker Endothelin 1 (ET-1) in a biological sample from a mammalian subject, particularly in the urine or urothelial tissue. An increased level of expression of ET-1 above the level of expression in the same sample of a healthy mammalian subject is an indication of a diagnosis of IC. Such diagnosis may further involve identify other clinical symptoms of IC. Additionally the method may use additional biomarkers, such as Hb-EFG, EGF, APF, IL-8, IL-6, and cGMP. Assay methods and diagnostic reagents and kits for such diagnosis are provided. Methods and compositions for treating IC by reducing the action, production or synthesis of ET-1 in the urine or urothelium and/or inhibiting its binding to its ET A and/or ET B receptors are also provided.

专利号:US-7888116-B2
优先权日:2004-07-22
标 题 :Uses of notch receptors, notch ligands, and notch modulators in methods related to metabolic diseases
发明人：EGAN JOSEPHINE M; DOYLE MAIRE E
权利人:US HEALTH
摘要:Disclosed are methods for identifying and isolating a precursor cell. Also, disclosed are methods of increasing insulin synthesis from a pancreatic B-cell. Further, disclosed are methods of improving pancreatic B-cell function. Still further, disclosed are methods of preventing or delaying the onset of a metabolic disease, methods of treating or preventing a metabolic disease in a subject, and to compositions for treating or preventing a metabolic disease in a subject in need of such treatment or prevention.

专利号:US-6977153-B2
优先权日:2002-12-31
标 题:Rolling circle amplification of RNA
发明人：KUMAR GYANENDRA; ABARZUA PATRICIO
权利人:QIAGEN GMBH
摘要:Disclosed are compositions and methods for amplification of RNA molecules. The disclosed method involves synthesizing first strand cDNA molecules from RNA molecules, circularizing the first strand cDNA molecules and replicating the circularized first strand cDNA molecules using rolling circle replication. The method can be aided by the use of specialized primers for cDNA synthesis and specialized probes for circularizing the first strand cDNA molecules. The method can be used to replicate and amplify multiple RNA molecules, such as all RNA molecules in a sample or all mRNA molecules in a sample, or be used to replicate and amplify specific RNA molecules. Rolling circle replication of the circularized first strand cDNA molecules results in long DNA strands containing tandem repeats of the cDNA sequence. The tandem sequence DNA can be used directly (for detection of sequences, for example), further amplified, or used any other purpose. Double-stranded tandem sequence DNA can be used to produce unit lengths of the cDNA sequence. Tandem sequence DNA can also be transcribed to produce transcripts having sequence complementary to or matching the sequence of RNA molecules.

专利号:US-8816095-B2
优先权日:2008-08-15
标题:Na channels, disease, and related assays and compositions
发明人：BROWN MILTON L; GRINDROD SCOTT; WALLS THOMAS H; HANSEN TODD; SUY SIMENG; PAIGE MIKELL A
权利人:BROWN MILTON L; GRINDROD SCOTT; WALLS THOMAS H; HANSEN TODD; SUY SIMENG; PAIGE MIKELL A; UNIV GEORGETOWN
摘要:Disclosed are molecules and their synthesis, for use in blocking gated ion channels such as voltage-gated sodium channels (VGSCs) and prostate voltage sodium channels (PVSCs). These inhibitors have superior blocking efficacy, for instance in displacing the radioligand [ 3 H]-Batrachotoxin-B ([ 3 H]-BTX-B) that binds to site 2 of a VGSC. The molecules of the invention comprise a moiety which increases the binding affinity of molecules for the protein binding site in prostate cancer cells (PCs), and which is also fluorescent. In one embodiment the invention molecules are an inhibition system that can be used to target over-abundant or hyperactive VGSCs selectively in pain, epilepsy or prostate cancer, inhibiting the proliferation of PCs. The fluorescent moiety also facilitates screening, tracking, and pharmacodynamic studies of the drug in a biological system both in vitro and in vivo.